Responses
Clinical/translational cancer immunotherapy
Original research
CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation
Compose a Response to This Article
Other responses
No responses have been published for this article.
